Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives
- PMID: 25574078
- PMCID: PMC4284336
- DOI: 10.3748/wjg.v21.i1.21
Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives
Abstract
Distinction between Crohn's disease of the colon-rectum and ulcerative colitis or inflammatory bowel disease (IBD) type unclassified can be of pivotal importance for a tailored clinical management, as each entity often involves specific therapeutic strategies and prognosis. Nonetheless, no gold standard is available and the uncertainty of diagnosis may frequently lead to misclassification or repeated examinations. Hence, we have performed a literature search to address the problem of differential diagnosis in IBD colitis, revised current and emerging diagnostic tools and refined disease classification strategies. Nowadays, the differential diagnosis is an untangled issue, and the proper diagnosis cannot be reached in up to 10% of patients presenting with IBD colitis. This topic is receiving emerging attention, as medical therapies, surgical approaches and leading prognostic outcomes require more and more disease-specific strategies in IBD patients. The optimization of standard diagnostic approaches based on clinical features, biomarkers, radiology, endoscopy and histopathology appears to provide only marginal benefits. Conversely, emerging diagnostic techniques in the field of gastrointestinal endoscopy, molecular pathology, genetics, epigenetics, metabolomics and proteomics have already shown promising results. Novel advanced endoscopic imaging techniques and biomarkers can shed new light for the differential diagnosis of IBD, better reflecting diverse disease behaviors based on specific pathogenic pathways.
Keywords: Advanced endoscopic imaging; Biomarkers; Crohn’s disease; Histopathology; Inflammatory bowel disease unclassified; Ulcerative colitis.
Figures
Similar articles
-
Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus.Endoscopy. 2009 Jul;41(7):618-37. doi: 10.1055/s-0029-1214790. Epub 2009 Jul 8. Endoscopy. 2009. PMID: 19588292 Review.
-
Inflammatory bowel disease. Part II: Clinical and therapeutic aspects.Dis Mon. 1991 Nov;37(11):669-746. doi: 10.1016/s0011-5029(05)80013-6. Dis Mon. 1991. PMID: 1935537 Review.
-
Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.J Pediatr Gastroenterol Nutr. 2007 May;44(5):653-74. doi: 10.1097/MPG.0b013e31805563f3. J Pediatr Gastroenterol Nutr. 2007. PMID: 17460505
-
Inflammatory bowel disease. Part I: Nature and pathogenesis.Dis Mon. 1991 Oct;37(10):605-66. doi: 10.1016/0011-5029(91)90024-6. Dis Mon. 1991. PMID: 1893828 Review.
-
Clinical presentation of Crohn's, ulcerative colitis, and indeterminate colitis: Symptoms, extraintestinal manifestations, and disease phenotypes.Semin Pediatr Surg. 2017 Dec;26(6):349-355. doi: 10.1053/j.sempedsurg.2017.10.003. Epub 2017 Oct 5. Semin Pediatr Surg. 2017. PMID: 29126502 Review.
Cited by
-
Reclassification of Inflammatory Bowel Disease Type Unclassified by Small Bowel Capsule Endoscopy.Medicina (Kaunas). 2023 Nov 23;59(12):2064. doi: 10.3390/medicina59122064. Medicina (Kaunas). 2023. PMID: 38138167 Free PMC article.
-
Oat Peptides Alleviate Dextran Sulfate Sodium Salt-Induced Colitis by Maintaining the Intestinal Barrier and Modulating the Keap1-Nrf2 Axis.Nutrients. 2023 Dec 9;15(24):5055. doi: 10.3390/nu15245055. Nutrients. 2023. PMID: 38140314 Free PMC article.
-
Short noncoding RNAs as predictive biomarkers for the development from inflammatory bowel disease unclassified to Crohn's disease or ulcerative colitis.PLoS One. 2024 Feb 26;19(2):e0297353. doi: 10.1371/journal.pone.0297353. eCollection 2024. PLoS One. 2024. PMID: 38408066 Free PMC article.
-
Virgin Olive Oil and Health: Summary of the III International Conference on Virgin Olive Oil and Health Consensus Report, JAEN (Spain) 2018.Nutrients. 2019 Sep 1;11(9):2039. doi: 10.3390/nu11092039. Nutrients. 2019. PMID: 31480506 Free PMC article. Review.
-
Intestinal granulomatous disease: what is the first call.BMJ Case Rep. 2018 Apr 19;2018:bcr2017223094. doi: 10.1136/bcr-2017-223094. BMJ Case Rep. 2018. PMID: 29674398 Free PMC article.
References
-
- Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54.e42; quiz e30. - PubMed
-
- Ng SC, Bernstein CN, Vatn MH, Lakatos PL, Loftus EV, Tysk C, O’Morain C, Moum B, Colombel JF. Geographical variability and environmental risk factors in inflammatory bowel disease. Gut. 2013;62:630–649. - PubMed
-
- Burisch J, Jess T, Martinato M, Lakatos PL. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7:322–337. - PubMed
-
- Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785–1794. - PubMed
-
- Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 Suppl A:5A–36A. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical